Siemens is a multi-industry company focused on the areas of automation, electrification, mobility, and healthcare. Its top three geographic regions-the United States, Germany, and China-contribute over half of group revenue. Siemens has a 75% investment in separately listed Siemens Healthineers. Recent portfolio activity included the listing of Siemens Energy, spinning out its power and gas and Siemens Gamesa business divisions in 2020.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
100.0%
暂无批准数据
- The global Pharma 4.0 market was valued at approximately USD 17.85 billion in 2024 and is forecast to reach USD 90.71 billion by 2034, expanding at a CAGR of 19.80%. - Robotics and automation dominate the technology segment, while manufacturing and quality control lead applications due to real-time process optimization and regulatory compliance demands. - North America holds the largest regional market share, supported by advanced pharmaceutical infrastructure, high R&D investment, and progressive regulatory frameworks. - Key growth drivers include digital transformation in pharmaceutical manufacturing, rising demand for biologics and personalized medicines, and regulatory mandates for data integrity and supply chain transparency.
- Siemens AG has agreed to acquire life sciences R&D software maker Dotmatics for $5.1 billion, marking its sixth-largest acquisition in company history and furthering its strategic shift toward software-focused operations. - The deal combines Dotmatics' scientific intelligence platform, used by over 2 million scientists globally, with Siemens' digital twin and AI capabilities to create an integrated solution spanning from R&D to manufacturing in life sciences. - Siemens expects the acquisition to expand its addressable market by up to $11 billion and generate near-term revenue synergies of approximately $100 million annually, growing to over $500 million in the long term.
